# To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction

> **NCT00526253** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Bioheart, Inc.** · enrollment: 170 (estimated)

## Conditions studied

- Congestive Heart Failure

## Interventions

- **BIOLOGICAL:** MyoCell
- **BIOLOGICAL:** MyoCell
- **PROCEDURE:** Hypothermosol

## Key facts

- **NCT ID:** NCT00526253
- **Lead sponsor:** Bioheart, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-09
- **Primary completion:** 2019-02
- **Final completion:** —
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00526253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00526253, "To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00526253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*